Kepler Cheuvreux Suisse SA Acquires Shares of 2,462 Amgen Inc. $AMGN

Kepler Cheuvreux Suisse SA acquired a new stake in Amgen Inc. (NASDAQ:AMGN) during the 1st quarter, HoldingsChannel.com reports. The institutional investor acquired 2,462 shares of the medical research company’s stock, valued at approximately $866,000.

Other hedge funds have also modified their holdings of the company. Brighton Jones LLC grew its position in Amgen by 23.5% in the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after acquiring an additional 5,226 shares during the period. Sivia Capital Partners LLC lifted its holdings in shares of Amgen by 10.6% during the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after acquiring an additional 114 shares during the period. Schnieders Capital Management LLC. boosted its stake in shares of Amgen by 29.3% in the 2nd quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock valued at $7,220,000 after purchasing an additional 5,853 shares in the last quarter. Main Street Financial Solutions LLC boosted its stake in shares of Amgen by 11.3% in the 2nd quarter. Main Street Financial Solutions LLC now owns 4,086 shares of the medical research company’s stock valued at $1,141,000 after purchasing an additional 416 shares in the last quarter. Finally, Ieq Capital LLC grew its holdings in shares of Amgen by 5.1% in the 2nd quarter. Ieq Capital LLC now owns 54,152 shares of the medical research company’s stock worth $15,120,000 after purchasing an additional 2,611 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on AMGN shares. UBS Group lifted their price target on shares of Amgen from $390.00 to $400.00 and gave the company a “buy” rating in a report on Monday, April 13th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Amgen in a research note on Thursday, June 18th. Canaccord Genuity Group began coverage on shares of Amgen in a report on Monday, April 20th. They set a “hold” rating and a $366.00 price objective for the company. Wall Street Zen cut shares of Amgen from a “buy” rating to a “hold” rating in a research note on Saturday, June 27th. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $350.00 target price on shares of Amgen in a report on Wednesday, April 8th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Amgen has a consensus rating of “Hold” and an average target price of $355.50.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $374.15 on Monday. The firm’s 50-day simple moving average is $342.43 and its 200 day simple moving average is $348.09. The company has a market cap of $201.93 billion, a price-to-earnings ratio of 26.04, a price-to-earnings-growth ratio of 3.68 and a beta of 0.41. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. Amgen Inc. has a 12-month low of $269.77 and a 12-month high of $391.29.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $4.77 by $0.38. The firm had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the company posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, research analysts expect that Amgen Inc. will post 22.39 earnings per share for the current fiscal year.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.85% of the stock is owned by company insiders.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.